Literature DB >> 19707857

KLF6 inhibits estrogen receptor-mediated cell growth in breast cancer via a c-Src-mediated pathway.

Jun Liu1, Tian Du, Yufeng Yuan, YueMing He, Zui Tan, Zhisu Liu.   

Abstract

Estrogen receptors play a key role in breast cancer development and progression. Kruppel-like factor 6 (KLF6) is a tumour-suppressing protein. The aim of this study was to identify the role of KLF6 inhibition in estrogen receptor(alpha) (ERalpha)-elicited breast cancer development. Protein expression levels were examined by western blot analysis and immunoprecipitation was used to analyse interactions between proteins. An MTT assay was used to study cell proliferation. We found that KLF6 mediates cell growth in ERalpha-positive breast cancer cells through interaction with the c-Src protein. This interaction causes inactivation of the Erk and Akt proteins. These pathways are critical for the proliferation and survival of breast cancer cells. We also established that KLF6 could not mediate cell growth in ERalpha-negative cells. We conclude that KLF6 can modulate ERalpha-mediated cell growth in breast cancer cells. The unique role of KLF6 in mediating cell growth in breast cancer cells opens up the possibility of a new therapeutic strategy for treating breast cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19707857     DOI: 10.1007/s11010-009-0237-8

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  28 in total

1.  Inactivation of the tumor suppressor Krüppel-like factor 6 (KLF6) by mutation or decreased expression in hepatocellular carcinomas.

Authors:  Xiu-cheng Pan; Zhi Chen; Feng Chen; Xiao-hong Chen; Han-yin Jin; Xiao-yan Xu
Journal:  J Zhejiang Univ Sci B       Date:  2006-10       Impact factor: 3.066

2.  Role of c-Src in human MCF7 breast cancer cell tumorigenesis.

Authors:  Lorena González; María Teresa Agulló-Ortuño; José Manuel García-Martínez; Annarica Calcabrini; Carlos Gamallo; José Palacios; Ana Aranda; Jorge Martín-Pérez
Journal:  J Biol Chem       Date:  2006-05-25       Impact factor: 5.157

Review 3.  Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer.

Authors:  Montserrat Muñoz; Laura G Estévez; Isabel Alvarez; Yolanda Fernández; Mireia Margelí; Ignasi Tusquets; Miguel Angel Seguí; Ana Lluch
Journal:  Cancer Treat Rev       Date:  2008-10-14       Impact factor: 12.111

4.  KLF6, a candidate tumor suppressor gene mutated in prostate cancer.

Authors:  G Narla; K E Heath; H L Reeves; D Li; L E Giono; A C Kimmelman; M J Glucksman; J Narla; F J Eng; A M Chan; A C Ferrari; J A Martignetti; S L Friedman
Journal:  Science       Date:  2001-12-21       Impact factor: 47.728

5.  Assignment of the human B-cell-derived (BCD1) proto-oncogene to 10p14-p15.

Authors:  S El Rouby; P H Rao; E W Newcomb
Journal:  Genomics       Date:  1997-08-01       Impact factor: 5.736

6.  c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis.

Authors:  B S Verbeek; T M Vroom; S S Adriaansen-Slot; A E Ottenhoff-Kalff; J G Geertzema; A Hennipman; G Rijksen
Journal:  J Pathol       Date:  1996-12       Impact factor: 7.996

7.  Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination.

Authors:  Analisa DiFeo; Goutham Narla; Jennifer Hirshfeld; Olga Camacho-Vanegas; Jyothsna Narla; Stephen L Rose; Tamara Kalir; Shen Yao; Alice Levine; Michael J Birrer; Tomas Bonome; Scott L Friedman; Richard E Buller; John A Martignetti
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

8.  Genetic alterations of the KLF6 gene in gastric cancer.

Authors:  Yong Gu Cho; Chang Jae Kim; Cho Hyun Park; Young Mok Yang; Su Young Kim; Suk Woo Nam; Sug Hyung Lee; Nam Jin Yoo; Jung Young Lee; Won Sang Park
Journal:  Oncogene       Date:  2005-06-30       Impact factor: 9.867

9.  Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1.

Authors:  Sharon Benzeno; Goutham Narla; Jorge Allina; George Z Cheng; Helen L Reeves; Michaela S Banck; Joseph A Odin; J Alan Diehl; Doris Germain; Scott L Friedman
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

10.  [Mutation analysis of KLF6 gene in human nasopharyngeal carcinomas].

Authors:  Han-kui Chen; Xiao-qiong Liu; Jie Lin; Tian-yu Chen; Qi-sheng Feng; Yi-xin Zeng
Journal:  Ai Zheng       Date:  2002-10
View more
  19 in total

Review 1.  Krüppel-like factors in cancer.

Authors:  Marie-Pier Tetreault; Yizeng Yang; Jonathan P Katz
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

2.  Identification of miRNAs that specifically target tumor suppressive KLF6-FL rather than oncogenic KLF6-SV1 isoform.

Authors:  Wei-Cheng Liang; Yan Wang; Li-Jia Xiao; Yu-Bing Wang; Wei-Ming Fu; Wei-Mao Wang; Hui-Qing Jiang; Wei Qi; David Chi-Cheong Wan; Jin-Fang Zhang; Mary Miu-Yee Waye
Journal:  RNA Biol       Date:  2014-06-12       Impact factor: 4.652

3.  Ah Receptor Pathway Intricacies; Signaling Through Diverse Protein Partners and DNA-Motifs.

Authors:  D P Jackson; A D Joshi; C J Elferink
Journal:  Toxicol Res (Camb)       Date:  2015-03-17       Impact factor: 3.524

4.  Lowly methylated region analysis identifies EBF1 as a potential epigenetic modifier in breast cancer.

Authors:  Nora Fernandez-Jimenez; Athena Sklias; Szilvia Ecsedi; Vincent Cahais; Davide Degli-Esposti; Antonin Jay; Pierre Benoit Ancey; Hae Dong Woo; Hector Hernandez-Vargas; Zdenko Herceg
Journal:  Epigenetics       Date:  2017-11-10       Impact factor: 4.528

5.  Human phosphatidylethanolamine-binding protein 4 promotes transactivation of estrogen receptor alpha (ERalpha) in human cancer cells by inhibiting proteasome-dependent ERalpha degradation via association with Src.

Authors:  Haibo Liu; Jianming Qiu; Nan Li; Taoyong Chen; Xuetao Cao
Journal:  J Biol Chem       Date:  2010-05-11       Impact factor: 5.157

6.  Nuclear expression of KLF6 tumor suppressor factor is highly associated with overexpression of ERBB2 oncoprotein in ductal breast carcinomas.

Authors:  Ricardo C Gehrau; Diego S D'Astolfo; Catherine I Dumur; José L Bocco; Nicolás P Koritschoner
Journal:  PLoS One       Date:  2010-01-28       Impact factor: 3.240

7.  Mutations and Krüppel-like factor 6 (KLF6) expression levels in breast cancer.

Authors:  Filiz Ozdemir; Mehtap Koksal; Vahit Ozmen; Ibrahim Aydin; Nur Buyru
Journal:  Tumour Biol       Date:  2014-02-12

8.  Kruppel-like factor 6 suppresses growth and invasion of hepatocellular carcinoma cells in vitro and in vivo.

Authors:  Pei-Hao Wen; Dong-Yu Wang; Jia-Kai Zhang; Zhi-Hui Wang; Jie Pan; Xiao-Yi Shi; Han Yang; Shui-Jun Zhang; Wen-Zhi Guo
Journal:  Int J Immunopathol Pharmacol       Date:  2016-08-10       Impact factor: 3.219

9.  PSG gene expression is up-regulated by lysine acetylation involving histone and nonhistone proteins.

Authors:  Soledad A Camolotto; Ana C Racca; Magali E Ridano; Susana Genti-Raimondi; Graciela M Panzetta-Dutari
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

10.  Krüppel-like factor 6 expression changes during trophoblast syncytialization and transactivates ßhCG and PSG placental genes.

Authors:  Ana C Racca; Soledad A Camolotto; Magali E Ridano; José L Bocco; Susana Genti-Raimondi; Graciela M Panzetta-Dutari
Journal:  PLoS One       Date:  2011-07-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.